Persistent HBV replication and serological response during up to fifteen years of tenofovir-based antiretroviral therapy in HIV-hepatitis B coinfecting patients: a multicenter prospective cohort study

Running title: Fifteen years of tenofovir in HIV-HBV coinfection

Lorenza N. C. Dezanet¹, Patrick Mialhes², Caroline Lascoux-Combe³, Julie Chas⁴, Sarah Maylin⁵, Audrey Gabassi^{5,6}, Hayette Rougier⁷, Constance Delaugerre^{5,6}, Karine Lacombe^{1,8}, Anders Boyd^{*8}

Institutional affiliations:

¹Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, F75012, Paris, France

²Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Service de Maladies Infectieuses et Tropicales, Lyon, F69317, France

³APHP, Hôpital Saint-Louis, Service de Maladies Infectieuses, Paris, F75010, France

⁴APHP, Hôpital Tenon, Service de Maladies Infectieuses, Paris, F75020, France

⁵APHP, Hôpital Saint-Louis, Laboratoire de Virologie, Paris, F75010, France

⁶Université de Paris, INSERM U944, Institut de Recherche Saint-Louis, F75010, Paris, France

⁷IMEA, Institut de Médecine et d'Epidémiologie Appliquée, Paris, F75018, France

⁸APHP, Hôpital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris, F75012, France

***Corresponding author:**

Dr. Anders Boyd

Services de Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine

184 Rue du Faubourg St. Antoine, 75571 Paris Cedex 12, France

Tel: +33 1 71 97 05 17

Fax: +33 1 49 28 21 49

27 Email: anders.boyd@iplesp.upmc.fr

28

Abstract

Objectives

To determine the extent of hepatitis B virus (HBV) suppression and its association with hepatitis “e” antigen (HBeAg) and hepatitis B surface antigen (HBsAg)-seroclearance in HIV-HBV-coinfected patients undergoing long-term tenofovir (TDF)-based antiretroviral therapy (ART).

Methods

We prospectively followed 165 HIV-HBV-coinfected patients undergoing TDF-based ART. Serum HBV-DNA viral loads, HBeAg and HBsAg were obtained at TDF-initiation and every 6-12 months. We calculated the proportion achieving virological response (VR, <60 IU/mL) during follow-up. We also calculated rates of HBeAg- and HBsAg-seroclearance, which were compared between those who achieved versus never achieved VR during follow-up using an exact binomial test.

Results

During a median 8.1 years (IQR=4.0-13.2) of TDF-treatment, 152 (92.1%) patients were able to achieve VR and 13 (7.9%) never achieved VR (median HBV-DNA at the end of follow-up=608 IU/mL, range=67-52,400,000). The prevalence of individuals with detectable HBV-DNA (≥ 60 IU/mL) decreased during TDF-treatment: 15.1% ($n=14/93$) at 5-years, 3.2% ($n=2/62$) at 10-years and, 3.2% ($n=1/31$) at 15-years. 44/96 HBeAg-positive patients (6.15/100 person-years) had HBeAg-seroclearance and 13/165 patients overall (0.87/100 person-years) had HBsAg-seroclearance. No difference in HBeAg-seroclearance was observed between those who achieved versus never achieved VR (7.4 versus 3.7/100 person-years, $p=0.33$), while HBsAg-seroclearance was only observed in those with VR (1.0 versus 0/100 person-years, $p=0.49$; respectively). Individuals with VR also had a higher frequency of undetectable HIV-RNA during treatment ($p<0.001$).

Conclusions

During long-term TDF-based ART for HIV-HBV coinfection, persistent HBV viremia is apparent, but becomes less frequent over time. HBsAg-seroclearance only occurred in those with full HBV and relatively high HIV suppression.

Introduction

In the past decade, liver-related mortality has continued to persist as one of the major causes of non-AIDS related deaths in HIV-positive patients.^{1,2} Coinfection with hepatitis B virus (HBV) has been implicated as a major reason for this finding.³ HBV infection by itself is associated with an increased risk of liver fibrosis progression, cirrhosis and hepatocellular carcinoma (HCC), which can be mitigated with effective HBV-DNA suppression.⁴ Given that tenofovir (TDF) has dual activity against HIV and HBV, long-term administration of TDF-containing antiretroviral therapy (ART) has been recommended for all HIV-HBV coinfecting patients.^{5,6}

Although TDF has a high genetic barrier to HBV resistance,⁷ at least 3 years of treatment may be required to achieve virological response,⁸⁻¹⁰ while 10-20% of HIV-HBV coinfecting patients exhibit persistence of HBV replication during longer periods of TDF.^{8,11-13} Nevertheless, almost all studies to date evaluating HBV replication during TDF have followed patients for at most 5-10 years and consequently, it is uncertain what proportion of patients achieve suppression of HBV-DNA viral load with longer TDF-use.^{8,14}

There are other therapeutic goals for improved prognosis, such as hepatitis B “e” antigen (HBeAg)-seroclearance (for those with HBeAg-positive serology) and importantly, hepatitis B surface antigen (HBsAg)-seroclearance. For TDF-treated HIV-HBV coinfecting patients, almost half of those who are HBeAg-positive exhibit HBeAg-seroclearance and few overall attain HBsAg-seroclearance.^{8,15,16} Since HBeAg-seroclearance and HBsAg-seroclearance seem to only occur among HIV-HBV coinfecting individuals undergoing TDF with sustained HBV virological response,⁸ there is concern regarding the consequences of persistent HBV replication on serological outcomes. Most of our understanding on HBV seroclearance rates also stems from studies of HIV-HBV coinfecting and HBV-monoinfecting patients with limited duration of TDF treatment.^{8,14}

In this study, we aimed to evaluate the extent of HBV suppression and determinants of various forms of HBV persistence in patients coinfecting with HIV-HBV undergoing up to 15 years of continuous TDF-based ART.

We further intended to examine the relationship between HBV persistence and HBeAg- and HBsAg-seroclearance.

Patients and Methods

Study population

Patients were selected from the French HIV-HBV Cohort Study.¹⁷ Briefly, this longitudinal cohort study included 308 HIV-positive patients with chronic HBV infection from four centers located in Paris and Lyon, France. Patients were included if they had HIV-positive serological results confirmed by western blot and HBsAg-positive serological results for >6 months. Participants were recruited in 2002-2003 and followed up prospectively every 6-12 months until 2017-2018. The cohort design and procedures are described elsewhere.^{17,18}

For this analysis, we included patients undergoing TDF-containing ART for ≥ 24 consecutive months. This timeframe was chosen since studies in HBV mono-infection and HIV-HBV coinfection have demonstrated that >90% achieve virological response within 24 months of nucleos(t)ide analogue (NA) therapy.¹⁹ We did not include patients with concomitant interferon/pegylated interferon (peg-IFN) or detectable hepatitis C virus (HCV) or hepatitis D virus (HDV) RNA.

Ethics

All patients provided written informed consent to participate in the study and the protocol was approved by the appropriate ethics committee (Paris, France) in accordance with the Helsinki Declaration.¹⁷

Data collection

Demographic information was collected at study inclusion. HIV-related variables included HIV-RNA viral load (HIV-VL) and CD4⁺ cell count, and were collected before TDF-initiation and at each follow-up visit. HBV-related variables included HBV-DNA VL, alanine aminotransferase (ALT) levels, aspartate aminotransferase

(AST) levels, qualitative HBeAg, anti-HBe antibodies, HBsAg, and anti-HBs antibodies, and were collected before TDF-initiation and at each follow-up visit. Cumulative exposure to viral replication was calculated using time-averaged copy-years over follow-up time (copy-years_{TAVG}), as detailed elsewhere.¹⁸ At TDF-initiation, L-nucleoside-associated HBV mutations at positions rt173, rt180, and rt204 of the *pol* gene and at nucleotide 1896 of the *precore* gene were determined using DNA chip technology (bioMérieux, Marcy l'Etoile, France).²⁰ Liver fibrosis was assessed at each yearly interval by the FibroTest® calculated from a standard battery of biochemical markers.²¹ METAVIR equivalents of this measure, as established in the HIV-HBV coinfecting population, were used to grade liver fibrosis (F2=0.48-0.58, F3=0.59-0.73, F4≥0.74).²²

HBV replication profiles

HBV replication profiles were based on HBV-viral load (VL) at the end of the follow-up, as defined previously.⁸ First, patients were classified on whether or not they had undetectable HBV-VL at the last follow-up visit (HBV-DNA <60 IU/mL). Second, those with undetectable HBV-VL were divided into two subgroups: sustained virological response (sustained-VR; achieving and/or constantly maintaining HBV-DNA <60 IU/mL thereafter) or transient persistent viremia (PV; attaining <60 IU/mL, intermittently ≥60 IU/mL thereafter and returning to undetectable levels at the last visit). Patients with detectable HBV-VL at the last visit were divided into two subgroups: low-level persistent viremia (LL-PV; 60-2,000 IU/mL) or high-level persistent viremia (HL-PV; >2,000 IU/mL).

Statistical analysis

Baseline was defined as the study visit at or directly before TDF-initiation. Follow-up began at TDF-initiation and continued until the last study visit, TDF-discontinuation, initiating peg-IFN, detection of HCV or HDV RNA, or death, whichever occurred first.

We used several sets of endpoints to evaluate HBV-DNA suppression. First, the percentage with undetectable HBV-DNA was calculated at the end of each yearly interval of follow-up. Second, the

cumulative proportion achieving VR (HBV-DNA <60 IU/mL) was calculated during continuous time. Third, in the subset of patients who had achieved VR, we identified visits at which HBV-DNA VL was detectable (≥ 60 /mL) after achieving VR [i.e. viral persistence]. Risk-factor analysis for viral persistence was performed on this subset of patients using follow-up that began at the first undetectable HBV-DNA VL and continued until right-censoring. Univariable odds ratios (OR) comparing the odds across levels of determinants over time and their 95% confidence intervals (95%CI) were calculated from a logistic regression model, which included a random-intercept to account for between-patient variation at baseline. A multivariable model was constructed by adding all covariables with a p value <0.20 in univariable analysis and removing nonsignificant variables in backward-stepwise fashion. Finally, we constructed HBV replication profiles as defined above. Comparisons between HBV replication profiles were performed for all clinical parameters at baseline and during follow-up using the Kruskal-Wallis test for continuous variables and Pearson's χ^2 test or Fisher's exact test for categorical variables. Scatterplots and locally weighted scatterplot smoothing plots were used to illustrate the evolution of HBV-DNA replication according to HBV replication profiles.

We then used HBeAg-seroclearance (for HBeAg-positive patients) and HBsAg-seroclearance as endpoints. We estimated the cumulative proportion achieving these events, while only considering the first seroclearance event and not taking into account transitioning back to antigen-positive status. We estimated time to seroclearance using Kaplan-Meier curves and the incidence of seroclearance rates, which were compared between those who achieved versus never achieved VR using a two-sided Exact binomial test with mid-p assumption.

All statistical analyses were performed using STATA software (v15.1; College Station, Texas, USA) and significance was determined using a p value < 0.05.

Results

Description of the study population

Of the 308 patients included in the cohort, 143 were not included in analysis for the following reasons: did not initiate TDF ($n=51$), used TDF for less than 24 months ($n=42$), used concomitant PEG-IFN or IFN ($n=20$), ever had anti-HCV and/or anti-HDV antibody positive serology ($n=23$), or had insufficient information at baseline ($n=7$). Thus, 165 individuals were included in the present analysis (Supplementary Figure 1).

Of these 165 patients, most were male (83.6%) with a median age of 41.7 years (IQR=36.4-48.3) at TDF-initiation (Table 1). Almost all patients had previously initiated ART (99.4%), with a median 7.0 years of ART exposure (IQR=4.4-9.2), and thus median CD4+ count was 410/mm³ (IQR=288-596) and 97 (58.8%) had undetectable HIV-RNA. At baseline, 96 (58.2%) patients were HBeAg-positive and HBV-DNA was detectable in 75.2% of participants. Of the 147 patients (89.1%) with previous lamivudine (LAM) exposure, median LAM duration was 5.1 years (IQR=2.8-6.8) at TDF initiation and, among those with available information, 20/100 (20.0%) had baseline LAM resistance mutations. HBV genotype was determined in 105 patients, and most harbored genotype A (67.6%), followed by G (15.2%), E (8.6%) and D (8.6%). Among patients with available data on Fibrotest scores at TDF initiation ($n=147$), 36 (24.5%) had F3-F4 fibrosis.

HBV-DNA suppression during TDF-containing ART

Patients were followed for a median 8.1 years (IQR=4.0-13.2), with a maximum follow-up of 15.7 years. Three patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide (TAF) based ART during follow-up, while follow-up during TAF was still included in analysis (median TAF duration: 0.5 years, range=0.2-5.6). The percentage of patients with undetectable HBV-DNA increased substantially in the first 6 years of TDF treatment, while, thereafter, ranging between 94.0-97.8% and never reaching 100% (Figure 1a).

163 (98.8%) patients were able to achieve virological response after a median 0.90 years (IQR=0.39-1.74) of follow-up and of them, 30 (18.2%) had at least one visit with detectable HBV-DNA after achieving virological response. The number of visits with detectable HBV-DNA for these patients were distributed as follows: 1, $n=17$; 2, $n=7$; 3, $n=2$; 4, $n=2$; 10, $n=1$; and, 18, $n=1$. Risk factors for viral persistence over time are given in

Table 2. In multivariable analysis, positive HBeAg status at baseline ($p=0.04$), lower nadir CD4+ cell counts ($p=0.002$) and undetectable HIV-VL ($p<0.001$) were significantly associated with viral persistence.

We then characterized HBV replication profiles based on HBV-VLs at the end of follow-up. Of the 152 (92.1%) patients with undetectable HBV-VL, 133 (87.5%) had remained undetectable (sustained-VR) and 19 (12.5%) had become detectable (median peak HBV-VL=2.54 $\log_{10}$ IU/mL, range=1.79-8.04) after having achieved undetectable HBV-VL (transient-PV). Among those with transient-PV, 10 had more than one visit with detectable HBV-DNA, with the time from first to last detectable HBV DNA measurement lasting a median 1.0 year (range=0.12-7.0). Of the 13 (7.9%) patients with detectable HBV-VL at the end of the follow-up, 9 had LL-PV (median HBV-VL=272 IU/mL, range=67-1,341) and 4 had HL-PV (range HBV-VL=3.91-7.72 $\log_{10}$ IU/mL). Of these patients, 11 had achieved HBV-VL <60 at least once during follow-up (LL-PV, $n=8$; HL-PV, $n=3$). The proportion of patients with undetectable HBV-VLs are summarized between groups in Figure 1b, while changes in HBV-VLs are given for patients with sustained-VR in Figure 1c, transient-PV in Figure 1d and LL-/HL-PV in Figure 1e.

At baseline, patients with transient-PV profile, as compared to sustained-VR, were significantly more likely to be HBeAg-positive ($p=0.04$), to have detectable HIV-VL ($p=0.04$), lower nadir CD4+ cell count ($p=0.002$), higher BMI ($p=0.01$), and shorter cumulative LAM treatment prior to TDF-initiation ($p=0.03$) (Table 3). Patients with LL-/HL-PV profiles had significantly higher baseline ALT ($p=0.007$) and AST levels ($p=0.03$), when compared to those with either sustained-VR or transient-PV. During follow-up, patients with sustained-VR profile, compared to transient-PV, were significantly more likely to achieve virological response at 24 months of therapy ($p=0.03$), showed higher frequency of suppressed HIV-VL ($p<0.001$) and lower frequency of liver fibrosis progression from mild or moderate fibrosis (F0-F1-F2) to more advanced fibrosis (F3-F4; $p=0.04$) (Table 4). When including only individuals with two or more visits with detectable HBV-DNA (after VR) in the transient-PV group, similar differences between groups were observed (data not shown). Individuals with LL-/HL-PV profiles, when compared to all other profiles, were significantly more likely to

have shorter duration of follow-up ($p<0.001$), higher 12-month ($p<0.001$) and 24-month change ($p<0.001$) in HBV-VL, higher maximum decrease ($p<0.001$) and increase ($p<0.001$) of ALT levels from baseline, and higher ALT levels at the last follow-up visit ($p<0.001$). Moreover, individuals with LL-/HL-PV profiles, compared to sustained-VR, had a lower frequency of undetectable HIV-VL for all visits during follow-up (Table 4).

HBeAg- and HBsAg-seroclearance and its relation to viral persistence during TDF-containing ART

Of the 96 HBeAg-positive patients at study inclusion, 44 lost HBeAg (cumulative incidence: 45.8%; 95%CI=35.6%-56.3%) after a median 4.9 years (IQR=3.0-9.0) of follow-up (incidence rate=6.1/100 person-years). Of them, 2 reverted back to HBeAg-positive serology and 4 changed serostatus multiple times until ending follow-up with HBeAg-negative serology. Of the 42 patients ending follow-up with HBeAg-negative serology, acquisition of anti-HBe antibodies (anti-HBeAb) was achieved in 14 (33.3%) patients either at the same visit as HBeAg-seroclearance ($n=10$) or from 1.7-11.4 years after HBeAg-seroclearance ($n=4$). Of these patients, 6 (42.9%) lost anti-HBeAb by the end of follow-up.

No difference was observed in HBeAg-seroclearance between those who were able to achieve VR during follow-up versus those who never achieved VR (7.4 versus 3.7/100 person-years respectively, $p=0.33$, Figure 2a). Of those who had HBeAg-seroclearance, 34 belonged to the sustained-VR, 8 transient-PV profile, and 2 LL-PV groups.

A total of 13 patients lost HBsAg (cumulative incidence: 7.9%; 95%CI=4.3%-13.1%) after a median 7.5 years (IQR=3.8-11.2) of follow-up (incidence rate=0.9/100 person-years). Of these patients, two reverted back to HBsAg-positive serology and one changed serostatus multiple times until ending follow-up with HBsAg-positive serology. Of the 10 patients ending follow-up with HBsAg-negative serology, acquisition of anti-HBsAb was achieved in six (60.0%) either at the same visit as HBsAg-seroclearance ($n=3$) or from 0.9-6.7 years after HBsAg-seroclearance ($n=3$). Additionally, 6 patients who lost HBsAg were HBeAg-positive at

baseline. For these patients, median time from HBeAg-seroclearance to HBsAg-seroclearance was 4.8 years (range=0.5-13.5).

HBsAg-seroclearance was only observed in those who achieved VR, yet this rate was not significantly different from those who were never able to achieve VR (1.0 versus 0/100 person-years, respectively, $p=0.49$, Figure 2b). Of those who had HBsAg-seroclearance, 11 belonged to the sustained-VR and 2 transient-PV profile groups.

Severe liver-related morbidity and mortality and its relation to viral persistence during TDF-containing ART

At TDF initiation, 4 patients had already experienced a severe liver-related event [portal hypertension $n=1$; HCC, $n=2$; haemorrhagic necrosis of liver, $n=1$]. Of them, 2 had sustained VR, 1 had transient PV and 1 had HL-PV. During TDF treatment, 3 patients developed portal hypertension (all with sustained VR profiles), 1 hepatorenal syndrome (HL-PV profile), 3 HCC (2 with sustained VR and 1 with LL-PV profiles), and 2 haemorrhagic necrosis of liver (1 with sustained VR and 1 with transient PV). Two deaths were the result of HCC (1 with sustained VR and 1 with LL-PV profile) and one from decompensated liver with HCC and complications due to septic shock (sustained-VR profile). All three patients who developed HCC during follow-up had METAVIR F3-F4 fibrosis at TDF initiation, as measured by the FibroTest®. Ultrasound revealed the presence of hepatic nodules for all three patients, along with steatosis ($n=2$) and portal vein thrombosis ($n=1$).

Discussion

Using longitudinal data from one of the longest studies to date on TDF-use in HIV-HBV coinfecting individuals, we observed that viral persistence continues to occur throughout TDF-treatment, with 18.2% of patients exhibiting detectable HBV-DNA after having achieved virological response. Nevertheless, the probability of having detectable HBV-DNA decreased as the duration of TDF increased and $\leq 6\%$ of patients consistently had detectable HBV-DNA every year after 6 years of TDF. These data support the durability of HBV

suppression associated with TDF-use and suggest that viral persistence does not mitigate long-term viral suppression.

The extent of persistent viremia in individuals with chronic HBV infection varies considerably across studies. When defining persistence based on HBV-DNA levels at a maximum 24 months of follow-up, we found that only 8% of patients presented with LL-/HL-PV. If minimum follow-up is extended to 60 months, where most HIV-HBV coinfecting individuals appeared to have achieved HBV virological suppression, only 4% of patients had LL-PV and no patient had HL-PV. The proportion of patients with HBV persistence in our study is considerably lower when compared to other prospective studies in HIV-HBV coinfecting, reporting 14% to 54%.^{8,9,12} However, these studies used inability to achieve virological response at 12-months as the basis for persistent viremia, which, given our data and others,⁹ is too short a timeframe to define persistence. When defining persistence based on any detection of HBV-VL after achieving VR, we found that 20% of individuals had at one point persistent viremia. In the GS-US-174-0102 and GS-US-174-0103 registration studies in HBV mono-infected patients, this type of persistence occurred very rarely (0.9%).²³

We observed that median CD4⁺ cell count at last follow-up visit and the frequency of undetectable HIV-VL over time were significantly higher in patients with sustained-VR compared to other profiles, while patients who had higher CD4⁺ counts for longer periods of time were able to more frequently suppress HBV-DNA replication after achieving initial virological response. Indeed, immunosuppression as an underlying factor for viral persistence has been evoked in other studies.^{12,15} Previous research has suggested that HIV-HBV coinfecting patients have lower levels of HBV-specific CD4⁺ T-cell responses,^{24,25} intrahepatic T cells, Kupfer cells and NK cells,²⁶ as well as reduced intrahepatic inflammatory activity when compared to HIV-positive patients without HBV infection. Taken together, these data highlight the importance of immunoregulation to control HBV replication and could explain why persistence occurs more frequently in HIV-HBV coinfecting versus HBV mono-infected patients.

Detectable HIV-RNA viremia was also more often observed during treatment for individuals with transient-PV, LL- and HL-PV profiles and was strongly associated with HBV viral persistence after achieving virological response. Similar findings have been observed by others.^{9,12} In general, detectable HIV-RNA, as determined by most commercial assays, is either due to developing HIV resistant variants or inadequate adherence to ART.²⁷ Given that no consistent mutation pattern for TDF resistance has yet to be observed,⁴ detectable HBV-DNA would likely be the result of poor adherence.²⁸ Much of the concordance of simultaneously detectable HIV-RNA and HBV-DNA would then likely be the result of insufficient adherence. We did not collect data on HIV resistance and our data on HBV sequences are limited to the first 8 years of follow-up, hence we are unable to confirm this speculation. TDF plasma concentrations were indeed lower or even undetectable for individuals with profiles of LL/HL-PV in our previous study,⁸ while others have found lower concentrations of intracellular drug levels of tenofovir-diphosphate, a measure of long-term adherence, for HIV-HBV coinfecting individuals with HBV persistent viremia during TDF-treatment.²⁹ Nevertheless, considering that HIV-RNA was undetectable for 71% of visits when HBV-VL was detectable (after initial HBV virological response), adherence alone cannot fully explain HBV persistent viremia.

For individuals with persistent viremia, it is clear that the vast majority are able to eventually suppress HBV-DNA. It remains debatable to what extent persistent viremia leads to major long-term serological consequences. We observed that individuals with LL- and HL-PV profiles were never able to achieve HBsAg-seroclearance. The reasons for this finding are not entirely clear. Large rebounds in HBV-DNA replication have been shown to be associated with HBsAg-seroclearance, but is usually accompanied with ALT flares and occurs mostly in HBV treatment cessation studies or during the course of natural infection;^{30,31} increases in ALT levels were rarely observed during HBV viral persistence in our study population of TDF-treated individuals. It could be that ability to achieve sustained VR is a proxy for tighter control of HBV viral activity in general; however, further evidence would be needed to confirm this finding. Nevertheless, it should be noted that only 7.9% of the entire study population were able to exhibit HBsAg-seroclearance, even after up

to 15 years of follow-up. The lack of function cure would appear to be more a general problem in treated
coinfecting patients.

The clinical consequences of persistent HBV viremia are also fairly unknown. From several studies during the
natural history of chronic HBV infection, consistently high levels of HBV-DNA (i.e. $\geq 10,000$ copies/mL) during
later phases of HBV infection are mostly associated with developing HCC and cirrhosis.³² Expectedly, our
data showed a low incidence of clinical liver-related outcomes, with no strong evidence that PV *per se* is
associated with higher rates of liver-related morbidity and mortality.

This study has several strengths, including possibly the longest follow-up to date in either HIV-HBV
coinfecting^{8,9,13,18} and HBV-monoinfected patients^{14,33} with consistently measured virological and serological
markers of HBV. However, certain limitations need to be addressed. First, the time-dependent definitions of
HBV replications profiles might be inadequate for under 3 years of follow-up. Therefore, we decided to also
use persistent viremia after initial VR as a complementary definition of persistence. Second, we did not
measure plasma TDF concentrations to assess adherence, so we cannot determine if those patients with
viral persistence were adherent to ART or whether a decrease in frequency of persistence was due to
improved adherence over time. Third, our data represent a population that is highly ART-experienced and
more immunosuppressed compared to contemporary patient populations, but still actively seen in
outpatient settings. Finally, since genotypic data were not collected at later years of TDF use in our cohort,
we are unable to determine whether viral persistence is related to certain mutational patterns.³⁴ From our
last analysis, there were only 9 additional patients exhibiting an HBV-VL > 1000 IU/mL, which would be ideal
for sequencing, and the small numbers would unlikely reveal any other mutation patterns explaining viral
persistence during TDF use.

In conclusion, we demonstrate that TDF is able to suppress HBV-DNA to undetectable levels in the majority
of ART-experienced HIV-HBV coinfecting patients undergoing up to 15 years of TDF-containing ART.

Nevertheless, a low proportion of patients do exhibit HBV viral persistence. A small proportion of patients achieved HBV functional cure, which was exclusively observed in those with sustained HBV-VLs. This low percentage of serological responders is quite similar to HBV mono-infected patients undergoing prolonged TDF treatment¹⁴ and highlights the need to identify novel HBV treatment strategies against HBV. Still, evaluating the relationship between HBV persistent viremia and more severe clinical outcomes is warranted in larger, longitudinal cohort studies.

Acknowledgements

The authors are grateful to the patients and the clinical teams for their commitment to the French HIV-HBV Cohort. This study was sponsored by the Institut de Médecine et d'Epidémiologie Appliquée (IMEA). L.N.C.D. was awarded a post-doctoral fellowship from the France REcherche Nord&sud Sida-hiv Hépatites (ANRS).

Role of each author. L.N.C.D. was responsible for the statistical analysis, interpretation of the data, and drafting the manuscript. S.M., A.G. and C.D. were responsible for interpretation of the data and drafting the manuscript. H.R., P.M., C. L-C., and J.C. acquired data for the cohort, assisted in interpreting data, and gave critical revisions of the manuscript. K.L. helped design, conceptualize, and obtain funding for the French HIV-HBV cohort study, coordinated data collection, and drafted parts of the manuscript. A.B. coordinated data analysis, gave important comments on data interpretation, drafted the manuscript, and provided critical revisions of the manuscript. All authors approved the final version.

Funding

This study was supported by SIDACTION (AO 19) and the ANRS. Gilead Sciences, Inc. provided an unrestricted grant for the French HIV-HBV cohort and was not involved in any part of the design, data collection, analysis and manuscript writing.

Transparency declarations

None to declare.

Supplementary Data

Figure S1 is available as Supplementary data.

References

1. Morlat P, Roussillon C, Henard S, *et al.* Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. *AIDS* 2014; **28**: 1181–91.
2. Sellier P, Hamet G, Brun A, *et al.* Mortality of People Living with HIV in Paris Area from 2011 to 2015. *AIDS Res Hum Retroviruses* 2020; **36**: 373–80.
3. Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, *et al.* Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. *AIDS* 2010; **24**: 1537–48.
4. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017; **67**: 370–98.
5. European AIDS Clinical Society. *EACS Guidelines version 10.1*. European AIDS Clinical Society. <https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html>
6. Price H, Dunn D, Pillay D, *et al.* Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis Ahn S-H, ed. *PLoS ONE* 2013; **8**: e68152.
7. Liu Y, Corsa AC, Buti M, *et al.* No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg– patients with chronic hepatitis B after 8 years of treatment. *J Viral Hepat* 2017; **24**: 68–74.
8. Boyd A, Gozlan J, Maylin S, *et al.* Persistent viremia in human immunodeficiency virus/hepatitis B coinfecting patients undergoing long-term tenofovir: Virological and clinical implications. *Hepatology* 2014; **60**: 497–507.
9. Hafkin JS, Osborn MK, Localio AR, *et al.* Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. *J Viral Hepat* 2014; **21**: 288–96.
10. Huang AJ, Núñez M. Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression. *J Int Assoc Provid AIDS Care* 2015; **14**: 360–8.
11. Audsley J, Bent SJ, Littlejohn M, *et al.* Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. *AIDS* 2016; **30**: 1597–606.

396 12. Matthews GV, Seaberg EC, Avihingsanon A, *et al.* Patterns and Causes of Suboptimal Response to
397 Tenofovir-Based Therapy in Individuals Coinfected With HIV and Hepatitis B Virus. *Clin Infect Dis* 2013; **56**:
398 e87–94.

399 13. de Vries–Sluijs TEMS, Reijnders JGP, Hansen BE, *et al.* Long-term Therapy With Tenofovir Is Effective for
400 Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus. *Gastroenterology* 2010;
401 **139**: 1934–41.

402 14. Marcellin P, Wong DK, Sievert W, *et al.* Ten-year efficacy and safety of tenofovir disoproxil fumarate
403 treatment for chronic hepatitis B virus infection. *Liver Int* 2019; **39**: 1868–75.

404 15. Huang Y-S, Sun H-Y, Chang S-Y, *et al.* Long-term virological and serologic responses of chronic hepatitis B
405 virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B
406 coinfection. *Hepatol Int* 2019; **13**: 431–9.

407 16. Boyd A, Maylin S, Moh R, *et al.* Hepatitis B surface antigen quantification as a predictor of seroclearance
408 during treatment in HIV-hepatitis B virus coinfecting patients from Sub-Saharan Africa: Seroclearance during
409 treatment. *J Gastroenterol Hepatol* 2016; **31**: 634–44.

410 17. Boyd A, Dezanet LNC, Kassime R, *et al.* Subclinical and Clinical Outcomes in Patients Coinfected With HIV
411 and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective,
412 Longitudinal Cohort Study. *JMIR Res Protoc* 2021; **10**: e24731.

413 18. Boyd A, Gozlan J, Mialhes P, *et al.* Rates and determinants of hepatitis B ‘e’ antigen and hepatitis B
414 surface antigen seroclearance during long-term follow-up of patients coinfecting with HIV and hepatitis B
415 virus: *AIDS* 2015; **29**: 1963–73.

416 19. Marcellin P, Zoulim F, Hézode C, *et al.* Effectiveness and Safety of Tenofovir Disoproxil Fumarate in
417 Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France. *Dig Dis Sci* 2016; **61**: 3072–83.

418 20. Lacombe K, Boyd A, Lavocat F, *et al.* High incidence of treatment-induced and vaccine-escape hepatitis B
419 virus mutants among human immunodeficiency virus/hepatitis B-infected patients. *Hepatology* 2013; **58**:
420 912–22.

421 21. Poynard T, Ngo Y, Munteanu M, Thabut D, Ratzu V. Noninvasive Markers of Hepatic Fibrosis in Chronic

422 Hepatitis B. *Curr Hepatitis Rep* 2011; **10**: 87–97.

423 22. Bottero J, Lacombe K, Guéchet J, *et al.* Performance of 11 biomarkers for liver fibrosis assessment in
424 HIV/HBV co-infected patients. *J Hepatology* 2009; **50**: 1074–83.

425 23. Gordon SC, Krastev Z, Horban A, *et al.* Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients
426 with chronic hepatitis B with high baseline viral load. *Hepatology* 2013; **58**: 505–13.

427 24. Chang JJ, Wightman F, Bartholomeusz A, *et al.* Reduced hepatitis B virus (HBV)-specific CD4+ T-cell
428 responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active
429 antiretroviral therapy. *J Virol* 2005; **79**: 3038–51.

430 25. Chang JJ, Sirivichayakul S, Avihingsanon A, *et al.* Impaired quality of the hepatitis B virus (HBV)-specific T-
431 cell response in human immunodeficiency virus type 1-HBV coinfection. *J Virol* 2009; **83**: 7649–58.

432 26. Iser DM, Avihingsanon A, Wisedopas N, *et al.* Increased intrahepatic apoptosis but reduced immune
433 activation in HIV-HBV co-infected patients with advanced immunosuppression. *AIDS* 2011; **25**: 197–205.

434 27. Panel on Antiretroviral Guidelines for Adults and Adolescents. *Guidelines for the Use of Antiretroviral*
435 *Agents in Adults and Adolescents with HIV*. Department of Health and Human Services.
436 <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf>

437 28. Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. *J Hepatology* 2012; **56**:
438 S112–22.

439 29. Wong TC, Lan A, Kiser JJ, *et al.* Novel quantification of tenofovir disoproxil fumarate adherence in human
440 immunodeficiency virus/hepatitis B coinfecting patients with incomplete hepatitis B virus viral suppression.
441 *Hepatology* 2016; **64**: 999–1000.

442 30. Avihingsanon A, Matthews GV, Lewin SR, *et al.* Assessment of HBV flare in a randomized clinical trial in
443 HIV/HBV coinfecting subjects initiating HBV-active antiretroviral therapy in Thailand. *AIDS Res Ther* 2012; **9**:
444 6.

445 31. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically
446 mediated liver disease. *Gastroenterology* 2001; **120**: 1009–22.

447 32. Chen C-J, Yang H-I. Natural history of chronic hepatitis B REVEAled. *J Gastroenterol Hepatol* 2011; **26**:

448 628–38.

449 33. Buti M, Fung S, Gane E, *et al.* Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated
450 with tenofovir disoproxil fumarate for up to 5 years. *Hepatol Int* 2015; **9**: 243–50.

451 34. Park E-S, Lee AR, Kim DH, *et al.* Identification of a quadruple mutation that confers tenofovir resistance in
452 chronic hepatitis B patients. *J Hepatology* 2019; **70**: 1093–102.

453

Table 1. Baseline characteristics among HIV/hepatitis B virus cohort participants (N=165).

Characteristic	N (%) or median (IQR)
Demographics	
Gender, male/female (% male)	138/25 (83.6)
Age, years*	41.7 (36.4-48.3)
BMI ≥ 25 Kg/m ² , N=149*	27 (18.1)
Born in high HBV endemic zone [†]	45 (27.3)
HIV characteristics	
Ever having an AIDS-defining illness [†]	41 (24.9)
Known HIV infection duration, years*	11.1 (7.10-15.0)
Detectable HIV-RNA [†]	68 (41.2)
HIV-RNA [‡] , log ₁₀ copies/mL*	4.1 (2.9-4.6)
CD4 ⁺ cell count, per mm ³ , N=164*	410 (288-596)
CD4 ⁺ nadir cell count, per mm ³ , N=152*	224 (104-319)
Duration of prior ART, years, N=164*	7.0 (4.4-9.2)
Viral hepatitis B characteristics	
Known HBV infection duration, years, N=164*	8.3 (4.2-12.1)

Prior LAM exposure [†]	147 (89.1)
Cumulative prior LAM treatment, years, N=147*	5.1 (2.8-6.8)
LAM-resistant mutations, N=100 [†]	20 (20.0)
Detectable HBV-DNA [†]	124 (75.2)
HBV-DNA [‡] , log ₁₀ IU/mL*	5.2 (3.2-7.2)
HBeAg-positive [†]	96 (58.2)
ALT, IU/L, N=161*	40 (26-68)
AST, IU/L, N=161*	34 (25-56)
F3-F4 fibrosis [#] , N=147 [†]	36 (24.5)
Precore mutations, N=101 [†]	22 (21.8)
HBV genotype, N=105 [†]	
A	71 (67.6)
D	9 (8.6)
E	9 (8.6)
G	16 (15.2)

*Median (IQR).

[†] Number (%).

[#] Estimated using the FibroTest®.

Abbreviations: AIDS, acquired immune deficiency syndrome; ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; BMI, body mass index; HBV, hepatitis B virus; HIV, human immunodeficiency virus; HBeAg, hepatitis B “e” antigen; LAM, lamivudine.

Table 2. Determinants of viral persistence (≥ 60 IU/mL) after having achieved virological response ($N=163$).

	<i>N</i> ^a	Univariable		Multivariable ^b	
		OR (95% CI)	<i>p</i> value	aOR (95% CI)	<i>p</i> value
Age at baseline, years	163	0.97 (0.91-1.04)	0.4		
Male gender	163	3.05 (0.54-17.35)	0.21		
High HBV-endemic zone	163	0.42 (0.11-1.58)	0.20		
BMI					
At baseline	147	1.06 (0.86-1.30)	0.6		
≥ 25 Kg/m ² at baseline	147	3.04 (0.79-11.76)	0.11		
During follow-up*	160	0.94 (0.90-0.99)	0.02		
Ever having an AIDS-defining illness	163	2.56 (0.73-8.92)	0.14		
Nadir CD4 ⁺ cell count (v/mm ³)	150	0.84 (0.75-0.93)	0.001	0.86 (0.78-0.95)	0.002
CD4 ⁺ cell count (v/mm ³)					
At baseline	162	0.88 (0.80-0.97)	0.01		
During follow-up*	163	0.99 (0.98-1.01)	0.30		
Undetectable HIV-RNA (≤ 50 copies/mL)	163	0.25 (0.12-0.55)	0.001	0.23 (0.10-0.51)	<0.001
HIV-RNA, log ₁₀ copies/mL [‡]	70	1.08 (0.58-2.00)	0.8		
HIV infection duration at baseline, years	163	0.98 (0.88-1.10)	0.7		

Duration of prior ART at baseline, years	163	0.95 (0.81-1.11)	0.5		
HBV infection duration at baseline, years	162	0.95 (0.86-1.06)	0.4		
Baseline HBV-DNA, log ₁₀ IU/mL [‡]	122	1.05 (0.77-1.42)	0.8		
HBeAg-positive					
At baseline	163	4.28 (1.24-14.71)	0.02	3.41 (1.08-10.78)	0.04
During follow-up*	163	0.97 (0.82-1.15)	0.7		
Previous LAM treatment	163	1.85 (0.27-12.69)	0.5		
Baseline LAM-resistant mutations	98	0.61 (0.08-4.53)	0.6		
Baseline <i>precore</i> mutations	99	1.53 (0.33-7.16)	0.6		
ALT >35 IU/mL					
At baseline	159	0.27 (0.08-0.93)	0.04		
During follow-up*	163	0.88 (0.76-1.03)	0.11		
AST >35 IU/mL					
At baseline	159	0.38 (0.12-1.20)	0.10		
During follow-up*	163	0.87 (0.74-1.02)	0.08		
F3-F4 fibrosis [#]	145	0.72 (0.19-2.73)	0.6		

*Time-dependent variables.

[‡] Among patients with detectable HIV-RNA or HBV-DNA viral loads.

[#] Estimated using the Fibrotest®.

^a Total number of patients in analysis.

^b BMI during follow-up was not considered in multivariable analysis because BMI <25, ≥ 25 Kg/m² at baseline was preferred. All ORs are adjusted for the variables listed in the column.

Abbreviations: AIDS, acquired immune deficiency syndrome; ALT, alanine aminotransferase; aOR, adjusted OR; ART, antiretroviral therapy; AST, aspartate aminotransferase; BMI, body mass index; HBV, hepatitis B virus; HIV, human immunodeficiency virus; HBeAg, hepatitis B “e” antigen; LAM, lamivudine.

Table 3. Baseline characteristics of hepatitis B virus replication profiles.

Characteristics	Sustained VR (N=133)	Transient PV (N=19)	LL-/HL-PV (N=13)	p value [§]
Demographics				
Gender, male/female (% male)	109/24 (82.0)	16/3 (84.2)	13/0 (100)	NS
Age, years*	42.3 (37.2-49.2)	39.7 (33.8-43.9)	39.8 (34.7-44.9)	NS
BMI, Kg/m ² , N=149*	22.3 (20.7-24.1)	23.7 (22.5-26.0)	22.2 (20.9-23.9)	1
Born in high HBV endemic zone [†]	38 (28.6)	5 (26.3)	2 (15.4)	NS
HIV characteristics				
Ever having an AIDS-defining illness [†]	30 (22.6)	8 (42.1)	3 (23.1)	NS
Known HIV infection duration, years*	11.3 (6.3-15.0)	10.1 (7.1-13.1)	10.2 (7.6-12.2)	NS
Detectable HIV-RNA [†]	51 (38.3)	12 (63.2)	5 (38.5)	1
HIV-RNA [‡] , log ₁₀ copies/mL*	3.7 (2.7-4.4)	4.4 (3.9-4.7)	4.3 (4.1-4.6)	NS
CD4 ⁺ cell count, per mm ³ , N=164*	440 (334-601)	262 (115-379)	500 (212-754)	1,3
CD4 ⁺ nadir cell count, per mm ³ , N=152*	238 (130-333)	121 (34-179)	96 (56-286)	1
Duration of prior ART, years, N=164*	7.0 (4.4-9.2)	7.6 (4.1-8.5)	6.4 (4.8-8.3)	NS

Viral hepatitis B characteristics

Known HBV infection duration, years, <i>N</i> =164*	8.3 (4.3-12.3)	9.3 (3.7-10.8)	6.1 (2.8-13.1)	NS
Prior LAM exposure [†]	118 (88.7)	16 (84.2)	13 (100)	NS
Cumulative prior LAM treatment, years, <i>N</i> =142*	5.5 (3.2-7.2)	3.8 (2.3-5.5)	4.9 (2.7-6.1)	1
Detectable HBV-DNA [†]	95 (71.4)	17 (89.5)	10 (76.9)	NS
HBV-DNA [‡] , log ₁₀ IU/mL*	5.2 (3.2-7.4)	4.6 (2.9-6.6)	6.6 (4.6-6.9)	NS
HBeAg-positive [†]	71 (53.4)	15 (79.0)	10 (76.9)	1
ALT, IU/L, <i>N</i> =161*	39 (26-68)	40 (23-64)	72 (54-145)	2,3
AST, IU/L, <i>N</i> =161*	33 (25-50)	28 (24-56)	66 (41-80)	2,3
F3-F4 fibrosis [#] , <i>N</i> =147 [†]	31 (26.5)	2 (10.5)	5 (38.5)	NS
LAM-resistant mutations, <i>N</i> =100 [†]	16 (20.3)	1 (9.1)	3 (30.0)	NS
<i>Precore</i> mutations, <i>N</i> =101 [†]	16 (20.5)	4 (30.8)	2 (20.0)	NS
HBV genotype, <i>N</i> =105 [†]				NS
A	54 (67.5)	9 (69.2)	8 (66.7)	
D	6 (7.5)	2 (15.4)	1 (8.3)	
E	6 (7.5)	2 (15.4)	1 (8.3)	
G	14 (17.5)	0 (0)	2 (16.7)	

*Median (IQR).

[†] Number (%).

[§] Significance was determined using Kruskal-Wallis' test for continuous variables and Pearson's chi-square test or Fisher's exact test for categorical variables. Significant differences ($p < 0.05$) between profile groups were indicated as follows: 1, sustained virological VR and transient PV; 2, sustained VR and LL-/HL-PV; 3, transient PV and LL-/HL-PV.

[¥] Among patients with detectable HIV-RNA or HBV-DNA viral loads.

[#] Estimated using the Fibrotest®.

Abbreviations: AIDS, acquired immune deficiency syndrome; ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; BMI, body mass index; cART, combined ART; HBV, hepatitis B virus; HBeAg, hepatitis B "e" antigen; HIV, human immunodeficiency virus; HL, high level; LAM, lamivudine; LL, low level; NS, no significant differences between groups; PV, persistent viremia; VR, virological response.

Table 4. Clinical and serological characteristics of hepatitis B virus replication profiles during follow-up.

Characteristics	Sustained VR (N=133)	Transient PV (N=19)	LL-/HL-PV (N=13)	p value [§]
Total follow-up, years*	8.1 (3.9-12.6)	13.7 (8.1-14.6)	4.1 (2.8-7.1)	1,2,3
HBV-DNA [‡]				
12-month change, log ₁₀ IU/mL*	-2.57 (-4.82, -0.85)	-2.80 (-4.70, -0.92)	-4.28 (-4.80, -2.80)	2,3
24-month change, log ₁₀ IU/mL*	-2.83 (-5.17, -1.10)	-1.58 (-4.80, -0.92)	-4.80 (-5.10, -2.80)	1,2,3
VR at 12 months [†]	86 (64.7)	10 (52.6)	7 (53.9)	NS
VR at 24 months [†]	110 (82.7)	11 (57.9)	9 (69.3)	1
VR at 36 months [†]	124 (93.2)	17 (89.5)	11 (84.6)	NS
HIV-RNA				
undetectable HIV VL in the last study visit [†]	123 (92.5)	19 (100.0)	10 (76.9)	NS
% undetectable HIV VLs during follow-up*	91.3 (80.0-100.0)	85.7 (52.9-91.3)	75.0 (58.3-88.2)	1,2
≥70% undetectable HIV VLs during follow-up [†]	111 (83.5)	11 (57.9)	8 (61.5)	1

Serological response				
HBeAg loss ^{†‡}	34 (25.6)	8 (42.1)	2 (15.4)	NS
HBeAg seroconversion ^{†‡}	13 (9.8)	1 (5.3)	1 (7.7)	NS
HBsAg loss [†]	11 (8.7)	2 (10.5)	0 (0)	NS
ALT				
Maximum decrease from baseline, IU/mL*	-12 (-39, -3)	-9 (-28, -2)	-84 (-92, -26)	1,2,3
Maximum increase from baseline, IU/mL*	9 (2-18)	12 (7-20)	51 (0-116)	1,2,3
Last follow-up visit, IU/mL	28 (21-36)	30 (18-39)	49 (32-78)	2,3
CD4 ⁺ cell count				
Last follow-up visit, IU/mL	540 (408-779)	460 (331-708)	408 (289-660)	1,2
Liver fibrosis [#]				
F3-F4 at last follow-up visit [†] , N=77	17 (28.8)	4 (36.4)	3 (42.9)	NS
Progression from F0-F1-F2 to F3-F4 ^{&†} , N=69	5 (9.8)	4 (36.4)	0 (0.0)	1

*Median (IQR).

[†]Number (%).

[‡]Among patients with detectable HBV-DNA at baseline.

[#]Among HBeAg-positive patients.

[#] Estimated using the Fibrotest®.

[&] From baseline to last follow-up visit, only in individuals with baseline F0-F1-F2 fibrosis.

[§] Significance was determined using Kruskal-Wallis' test for continuous variables and Pearson's chi-square test or Fisher's exact test for categorical variables. Significant differences ($p < 0.05$) between profile groups were indicated as follows: 1, sustained virological VR and transient PV; 2, sustained VR and LL-/HL-PV; 3, transient PV and LL-/HL-PV.

Abbreviations: ALT, alanine aminotransferase; HBeAg, hepatitis B "e" antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HIV, human immunodeficiency virus; HL, high level; LL, low level; PV, persistent viremia; VL, viral load; VR, virological response.

Figure legends

Figure 1.

Viral suppression during tenofovir (TDF)-treatment in (a) all patients and (b) different profiles of HBV replication; and HBV-DNA viral loads during TDF-treatment in patients with (c) sustained virological response (VR), (d) transient persistent viremia (PV), and (e) low-level/high-level persistent viremia (LL-/HL-PV). Individual levels are expressed as gray lines.

Figure 2.

Cumulative probability of (a) hepatitis B 'e' antigen (HBeAg) and (b) hepatitis B surface antigen (HBsAg) seroclearance, according to different profiles of HBV replication.

Figure 1.

Figure 2.

(a)

(b)